Theranexus
Clinical-stage biopharmaceutical company developing treatments for rare neurological disorders.
ALTHX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013286259
- LEI:
- 969500BFCV6IC7MFQP20
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://www.theranexus.com/en/
- Sector:
- Manufacturing
Description
THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-07-03 07:30 |
THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE '2024 RESEARCH…
|
English | 906.8 KB | ||
| 2024-07-03 07:30 |
THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP, LAURÉ…
|
French | 852.3 KB | ||
| 2024-06-06 07:30 |
Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/I…
|
English | 432.3 KB | ||
| 2024-06-06 07:30 |
Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans…
|
French | 394.5 KB | ||
| 2024-05-02 07:30 |
MISE A DISPOSITION DU DOCUMENT D'ENREGISTREMENT UNIVERSEL 2023
|
French | 281.5 KB | ||
| 2024-04-30 18:07 |
URD 2023
|
French | 12.5 MB | ||
| 2024-04-29 18:20 |
THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT
|
English | 383.5 KB | ||
| 2024-04-29 18:00 |
THERANEXUS PUBLIE SES RESULTATS ANNUELS 2023 ET FAIT LE POINT SUR SES ACTIVITÉS
|
French | 394.9 KB | ||
| 2024-04-26 18:00 |
Information mensuelle relative au nombre total de droits de vote et d'actions c…
|
French | 240.7 KB | ||
| 2024-04-23 07:30 |
Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the '…
|
English | 462.7 KB | ||
| 2024-04-23 07:30 |
Theranexus, Diverchim et l'INSERM bénéficient d'un financement de 4.7 millions …
|
French | 465.8 KB | ||
| 2024-04-18 18:00 |
Theranexus and BBDF announce final and positive safety and efficacy data in the…
|
English | 263.5 KB | ||
| 2024-04-18 18:00 |
Theranexus et BBDF annoncent les données finales et positives de sécurité et d'…
|
French | 289.7 KB | ||
| 2024-02-14 18:00 |
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN U…
|
English | 294.1 KB | ||
| 2024-02-14 18:00 |
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2023 ET FAIT UN POIN…
|
French | 269.5 KB |
Automate Your Workflow. Get a real-time feed of all Theranexus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Theranexus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Theranexus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
